Pacira down 25% as FDA approves generic version of Exparel
2024-07-02
jmiks Pacira BioSciences (NASDAQ:PCRX) plummeted ~25% in Tuesday trading after the U.S. FDA approved a generic version of Exparel (bupivacaine liposome), a non-opioid used for post-surgery local anasthesia. The agency approved an abbreviated New Drug Application for a generic version from Hengrui Pharma. Exparel is by far Pacira’s biggest revenueContinue Reading